Neonatal vaccination with 'universal strength' BCG vaccine.
'Universal strength' BCG vaccine was given to 219 neonates and 2 months later 159 infants were Mantoux-tested with 5 Tu PPD-S and their BCG scars measured. The results showed a satisfactory conversion rate of over 90%. Though 30% of the lesions discharged, this only lasted for a few days and the vaccine was well tolerated and acceptable for use in neonates.
D001500:BCG Vaccine / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D006113:United Kingdom
D001500:BCG Vaccine